A new health operator is preparing to open an emergency room at the former Affinity Medical Center in Massillon. The Massillon Community Health and Innovation Center is planning to offer medical ...

Full approval is contingent upon positive results from confirmatory trials. Loncastuximab tesirine is a CD19-directed antibody and alkylating agent currently FDA-approved to treat refractory or ...

Enrollment in the LOTIS-5 trial of loncastuximab tesirine-lpyl with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma has been completed. The phase 3, confirmatory LOTIS-5 ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for ...